Genmab — November 2019

[Bulder]

Webprogram Unavailable

(ash.confex.com)

[E_L]

154 matches in the search for "daratumumab"...

[Bulder]

Gen3013 in oral session

[E_L]

758 First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas https://ash.confex.com/ash/2019/webprogram/Paper121460.html

[E_L]

4066 Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies https://ash.confex.com/ash/2019/webprogram/Paper125765.html

[Bulder]

deres hjemmeside er åbenbart allerede gået ned

[GeorgeBest]

PM fra Genmab https://ir.genmab.com/news-releases/news-release-details/genmab-announces-data-be-presented-2019-ash-annual-meeting

[E_L]

thks, that makes life easier

[Bulder]

h
ex-cd38 https://ash.confex.com/ash/2019/webprogram/Paper125788.html

[E_L]

Mim8 utilized the Duobody platform / Novo Nordisk / hemophilia A https://ash.confex.com/ash/2019/webprogram/Paper122817.html

[Bulder]

Flot indtil videre. Gen3013 oral, og endvidere 6 orale dara præsentationer. Og chance for Andromeda som LB.

[Bulder]

7 orale

[Solsen]

Fandme flot !

[Solsen]

Så slipper konen for at tale med mig i aften

[Peter_Panik]

@ The Note 10.30. Jeg har længe og er stadig yderst positiv på Genmab, og der kommer jo den ene gode historie efter den anden. Vi kan jo og har tidligere set, at andre "store" spillere har en trading interesse i aktien både på den korte og mellemlange bane, og det kan give udsving, som river de nervøse midt over.

[Bulder]

Vigtigt gen3013: All CRS events were non-severe and did not lead to discontinuation.

[E_L]

i think that is the most important line I take away from it for now; safety was Jan's biggest concern, wasn't it. Seems ok so far.

[gentogen]

Lidt Ofa: HCVAD-O is a safe and highly effective regimen in pts with CD20+ Ph-negative B-ALL. This regimen achieves excellent outcomes in the AYA population (...) All but 1 pt (98%) achieved CR (2 after 2 cycles)...Using historical control pts, there was a trend towards improved OS with HCVAD-O versus HCVAD-R

[Solsen]

hexacd38 ser også spændende ud specielt i new diagnosed

[gentogen]

The preliminary analysis of the GELLC7 trial showed that the addition of consolidation with ofatumumab after 12 cycles of prior treatment with ibrutinib was well tolerated and elicited a deeper response.(...)In 20 patients receiving the consolidation with ofatumumab an improvement in response was observed, with 8/20 patients (40%) attaining a CR (7 patients converted PR to CR, and one patient SD to CR